MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
-
Published:2022-04-28
Issue:4
Volume:3
Page:471-485
-
ISSN:2662-1347
-
Container-title:Nature Cancer
-
language:en
-
Short-container-title:Nat Cancer
Author:
Alborzinia HamedORCID, Flórez Andrés F.ORCID, Kreth Sina, Brückner Lena M., Yildiz UmutORCID, Gartlgruber Moritz, Odoni Dorett I., Poschet GernotORCID, Garbowicz Karolina, Shao Chunxuan, Klein Corinna, Meier Jasmin, Zeisberger Petra, Nadler-Holly Michal, Ziehm MatthiasORCID, Paul Franziska, Burhenne Jürgen, Bell Emma, Shaikhkarami Marjan, Würth RobertoORCID, Stainczyk Sabine A.ORCID, Wecht Elisa M., Kreth Jochen, Büttner Michael, Ishaque Naveed, Schlesner Matthias, Nicke Barbara, Stresemann Carlo, Llamazares-Prada María, Reiling Jan H., Fischer MatthiasORCID, Amit IdoORCID, Selbach MatthiasORCID, Herrmann CarlORCID, Wölfl Stefan, Henrich Kai-Oliver, Höfer ThomasORCID, Trumpp Andreas, Westermann FrankORCID
Abstract
AbstractAberrant expression of MYC transcription factor family members predicts poor clinical outcome in many human cancers. Oncogenic MYC profoundly alters metabolism and mediates an antioxidant response to maintain redox balance. Here we show that MYCN induces massive lipid peroxidation on depletion of cysteine, the rate-limiting amino acid for glutathione (GSH) biosynthesis, and sensitizes cells to ferroptosis, an oxidative, non-apoptotic and iron-dependent type of cell death. The high cysteine demand of MYCN-amplified childhood neuroblastoma is met by uptake and transsulfuration. When uptake is limited, cysteine usage for protein synthesis is maintained at the expense of GSH triggering ferroptosis and potentially contributing to spontaneous tumor regression in low-risk neuroblastomas. Pharmacological inhibition of both cystine uptake and transsulfuration combined with GPX4 inactivation resulted in tumor remission in an orthotopic MYCN-amplified neuroblastoma model. These findings provide a proof of concept of combining multiple ferroptosis targets as a promising therapeutic strategy for aggressive MYCN-amplified tumors.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference57 articles.
1. Lin, C. Y. et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 151, 56–67 (2012). 2. Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and cancer. Cancer Discov. 5, 1024–1039 (2015). 3. Murphy, D. J. et al. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14, 447–457 (2008). 4. Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202–2211 (2010). 5. Westermann, F. et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 9, R150 (2008).
Cited by
105 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|